Objective: A shortage of blood products is predicted for the near future in many countries all over the world. Preoperative autologous blood donation (PABD) in cardiac surgery is considered an option to reduce the need of allogeneic blood products. We analysed a 1-year period of our institutional database according to the safety and efficiency of our autologous blood donation programme. Methods: All patients who donated autologous blood prior to cardiac surgery were matched to a non-donor according to age, body weight, body mass index, sex, haemoglobin concentration, EuroSCORE, antifibrinolytic therapy and risk for bleeding. We analysed the occurrence of adverse effects during donation in all donors as well as the main perioperative data, haemoglobin levels and the need for allogeneic blood transfusion in all patients. Results: There were no major cardiac events such as myocardial infarction, worsened cardiac insufficiency or death in the donor group during the PABD process. A total of 216 patients could be matched. Exposure to allogeneic blood products was significantly reduced in the donor group (packed red cells 70 patients (pts) vs 118 pts ( p < 0.001), fresh frozen plasma 26 pts vs 54 pts ( p = 0.001), platelets 10 pts vs 22 pts ( p = ns)). There were no reports of transfusion-related side effects. Further, there was no difference in haemoglobin concentrations at postoperative day 1 and at discharge. Conclusions: In this large matched-pair analysis without the need for risk stratification, PABD reduces the need for allogeneic blood products in adult cardiac surgery. In a carefully selected cohort, PABD is a safe and efficient alternative to allogeneic transfusion. #
Introduction
A tremendous shortage of allogeneic blood products in the near future is predicted for many countries in the European Union [1] . An increasingly older population, which can be treated by more sophisticated surgical skills, needs a larger amount of allogeneic blood products. By contrast, all efforts to increase the number of allogeneic blood products did not reach the intended target. As a matter of fact, demographic changes lead to an older donor population. These older donors drop out of the donation programme step by step due to diseases, age or physical condition, while the number of young adults willing to donate blood is reduced, again due to demographics. This imbalance between supply and demand might lead to rising prices and/or shortfalls in supply with allogeneic blood products. To prevent a dip in the supply of blood products for our future patients, clinicians should make all efforts to improve blood-conservation strategies.
Most of the packed red cells (PRCs) are used in surgical patients; up to 30% of the donated blood is transfused in cardiac surgery, where 40-60% of the patients receive transfusions during the perioperative course [2] . Most of the procedures are elective cases in clinically stable patients and the preoperative waiting time could be used for the planning of an optimal blood-conservation strategy. One option to reduce the rate of allogeneic transfusions is preoperative autologous blood donation (PABD). It is often a matter of discussion whether autologous blood donation in this special collective is safe and effective [3] [4] [5] [6] . In this study, a matched-pair analysis focussing on the risk of obtaining allogeneic blood in autologous blood donors was performed.
Material and methods
After approval by the Ethical Committee of the Technical University Munich (Germany), we performed a retrospective case-control analysis on data of all adult patients undergoing elective cardiac surgery with extracorporeal circulation at a university-affiliated clinic in the year 2006. All these patients (n = 1228) were invited to our PABD programme. Interested patients (n = 292) contacted our office and were examined by an experienced anaesthesiologist. Exclusion criteria for PABD were severe aortic valve stenosis defined as a systolic gradient >80 mmHg or a history of syncope, unstable angina, a haemoglobin (Hb) concentration <11 g dl À1 , coagulation disorders, acute infection of any kind, an intervention with a potential bacteraemia within the previous 3 days and a time interval <5 days prior cardiac surgery. After a positive evaluation, an informed consent for PABD was obtained from the patient.
The PABD evaluation and the donation itself were performed by a cardiac anaesthesiologist experienced in blood donation in the outpatient basis in the German Heart Centre Munich. There were between one and three donations per patient, depending on haemoglobin concentration and the time frame until surgery. The target volume of each donation was 480 ml whole blood. The removed volume was replaced either by 500 ml crystalloids, in case of volumedependent diseases (i.e. valvular stenosis) or by 500 ml colloids. The whole blood was processed to 1 unit of PRC and 1 unit of fresh frozen plasma (FFP) or alternatively leucocyte filtered and stored as whole blood (WB). The products were stored under temperature control in a separate storage unit for autologous blood products. The maximum shelf life of the packed cells and WB is 42 days and FFP up to 1 year. An oral substitution of 200-300 mg ferric sulphate was recommended from registration for PABD until admission for surgery. Erythropoietin was not used in any patient.
The first predonation sampling was usually not performed prior to 35 days before the scheduled day of admission, and the last predonation not later than 1 week before admission.
All data of the patients were prospectively collected in the clinical database as part of the national quality assurance project in cardiac anaesthesia and surgery. Laboratory values were extracted from the database of the clinical laboratory.
A balanced anaesthesia using sufentanil, midazolam, rocuronium and sevoflurane was performed. For extracorporeal circulation, a standard cardiopulmonary bypass (CPB) setting with a membrane oxygenator and non-heparinised tubes was used. According to our institutional protocol, either aprotinin or tranexamic acid (TxA) was used as an antifibrinolytic prophylaxis in every patient. Intra-operatively in all procedures cell salvage was used. Postoperatively, mediastinal shed blood was retransfused within the first 6 h if drainage volume exceeded 600 ml. Transfusion triggers were a haematocrit decrease to <18% on CPB or <24% during the postoperative course or if the patient showed clinical signs indicating the need for a higher oxygen supply (i.e. mixed venous oxygen saturation below 70%, tachycardia, hypotension, fatigue and orthostatic dysregulation). With ongoing bleeding, FFP was transfused for coagulation disorders such as a prothrombin time below 40%; platelets were transfused at a platelet count below 50 G l À1 . Transfusion triggers for autologous and allogeneic blood products were identical.
Participants in the PABD programme (donor group) were matched to non-donors (non-donor group) according to the most important predicting factors of perioperative allogeneic blood transfusion: [7] factors affecting the patient's preoperative RBC mass (age, body weight, body mass index, haemoglobin concentration and sex) and factors affecting the perioperative blood loss (EuroSCORE, antifibrinolytic medication and risk for bleeding) ( Table 1) .
Matching was achieved if all parameters were within the a priori-determined ranges. If a patient could not be matched sufficiently, data of the donor were removed from further analysis.
We analysed the main demographic data and perioperative data. Primary outcome was the amount of transfused allogeneic blood products. In addition to the entire donor group, a subgroup analysis with two subgroups, namely subgroup 1 donation (D1) and subgroup 2 or 3 donations (D2/ 3), was performed.
Continuous data are presented as mean AE standard deviation (SD), categorical variables as number (N) and incidence (%). Parameters were compared between group donor and group non-donor using Mann-Whitney U test for continuous variables and chi-square test for categorical variables. The results of the two-sided tests were considered significant if the p value was less than 0.05. For multiple comparisons a Bonferroni correction was performed. The statistical analyses were performed by SPSS for Windows 14.0 statistical software package (SPSS Inc., Chicago, IL, USA).
Results
In the year 2006, 237 patients were included in our institutional PABD programme.
There were no major adverse events such as myocardial infarction, stroke or death in the donor group during the PABD process. In 216 cases, a patient of the non-donor population could be matched according to our criteria; 21 donors were excluded from further analysis due to a unfeasible matching. The distribution of matching characteristics is shown in Table 1 .
The 216 successfully matched patients donated 396 units of autologous blood; 61 patients had one donation, 130 had two donations and 25 patients had three donations.
There was no difference in Hb concentration before the first donation of the donor group versus preoperative Hb in non-donor group (14.4 AE 1.4 g dl À1 vs 14.1 AE 1.3 g dl À1 ). The preoperative Hb concentration of the donors was significantly lower than that of the non-donors (13.1 AE 1.3 g dl À1 vs 14.1 AE 1.3 g dl À1 , p < 0.001). In the postoperative course, there was no difference in Hb upon arrival at the intensive care unit (ICU) (11.0 AE 1.6 g dl À1 vs
11.3 AE 1.7 g dl À1 ), the first postoperative day (POD1) (11.1 AE 1.4 g dl À1 vs 11.3 AE 1.4 g dl
À1
) and at discharge (11.3 AE 1.5 g dl À1 vs 11.4 AE 1.4 g dl À1 ) between the donor and the non-donor groups ( Table 2) .
The rate of autologous products not used and secondary discarded was PRC 21%, FFP 21% and WB 17% ( Table 3) .
The number of patients receiving allogeneic PRC (32% vs 55%, p < 0.001) or FFP (12% vs 25%, p = 0.001) was significantly lower in the donor group.
Regarding the absolute number of transfused allogeneic blood products, there was a significantly increased use in the non-donor group in PRC (471 vs 211, p < 0.001) and FFP (316 vs 173, p = 0.001). Subgroup analysis showed significantly lower values for PRC (28% vs 54%, p < 0.001) and FFP (11% vs 23%, p = 0.004) in the group D2/3, while the D1 group did not reach significance (Table 4) . 
Discussion
Matched-pair analysis demonstrated that PABD is efficient in reducing the transfusion rate of allogeneic PRC and FFP, if more than one donation is performed. We recorded no PABDrelated serious adverse event.
Efficiency is the most important postulation clinicians demand from a medical therapy. In this analysis, the donor group showed an approximately 50% reduction in the incidence and number of allogeneic transfusion requirements in all three components. In our cohort, even in the D2/3 group, the delay between last donation and surgery was approximately 14 days, which necessitates a weekly donation starting about 3-5 weeks before surgery. The consequent use of the optional 6-week donation period should achieve an increased recovery of the red cell mass and therefore decrease the difference in preoperative Hb levels compared to non-donors even without erythropoietin therapy, just with oral iron supplementation. This might result in a further reduction in allogeneic PRC transfusions. Although, even in the D1 group, the incidence of patients and the number of transfused allogeneic blood products were lower, this difference did not reach statistical significance. One main requirement for an optimal PABD timetable is a reliable date for surgery that guarantees adequate time for the PABD programme. This period of 42 days (including a reserve of 7 days until expiration of the blood products) often cannot be achieved. Therefore, the lower preoperative Hb level in our donor population is a tribute of the incomplete recovery of the red cell mass during the donation process and reflects a suboptimal delay between last donation and date of surgery [8] . Interestingly, the preoperative Hb level and the interval between last donation and surgery in the donor subgroups D1 and D2/3 were similar. This indicates that two to three donations were more effective in increasing preoperative blood cell mass. Consequently, in the D2/3 subgroup, the number of patients that needed an allogeneic PRC was lower than in the D1 subgroup (28% vs 44%).
The criticism in some reviews about an overall increased exposure to red blood cell transfusion was that each transfused product bears the risk of bacterial contamination or ABO incompatibility in case of administrative errors regardless of whether autologous or allogeneic products are transfused [6, 7, 9, 10] . Bacterial contamination of allogeneic PRC is found in about 0.03% [11, 12] , but septic transfusion reactions due to contamination is estimated to occur in 1 in 250 000 [11] . In autologous PRC, some authors noted a similar contamination rate of approximately 0.03% but there are not enough data to permit a quantitative risk assessment [12] . Strict consideration of donation and manufacturing guidelines established in allogeneic donors should lead to an equivalent low incidence of bacterial contamination in autologous blood products and make transfusion-related sepsis a rare event.
Mistransfusion, the most common non-infectious complication, occurs in 1 in 14 000 to 1 in 38 000 PRC transfusions [13, 14] . In PABD, this rate might be lower than for allogeneic transfusions because autologous products have a unique label containing the patient's personal data in addition to barcode and blood group on each component that is severally checked by the manufacturer, blood bank staff, transfusing staff and the patient himself. In fact, there are not enough data about the mistransfusion rates for autologous blood products available to perform a comparison to allogeneic products.
Judging the risk of autologous blood products, one should remember that there are several immune mediated noninfectious serious hazards of allogeneic blood transfusion that can be avoided with PABD. Febrile non-haemolytic transfusion reactions, allergic/anaphylactic transfusion reactions, post-transfusion purpura, graft-vs-host disease, transfusion-related immunomodulation, alloimmunisation and transfusion-related acute lung injury (TRALI) occur more or less frequently; but, nevertheless, some of them are lifethreatening complications. Especially TRALI increased the number of transfusion-related deaths within the past years [15] . The driving force to focus on PABD in the 1980s was the transmission of HIV to blood recipients. Large improvements in donor testing meanwhile reduced the risk of transmitting HIV (1:2 300 000), hepatitis C (1: 1 800 000) and hepatitis B (1: 350 000) [16] . However, besides these infections, there are many other infectious diseases that potentially could be transmitted by blood products -for example, malaria, Chagas, West Nile and Creutzfeldt-Jakob disease. There is no donor screening for these diseases which, in the future, might spread worldwide by increasing travel, climate changes and immigration [17] . The risk of a new infectious disease (i.e. H1N1 and H5N1 Flu) that could be transmitted by allogeneic blood transfusion remains a 'fixed and inevitable property of transfusion medicine' [18] . This scenario would increase the national economic costs of blood transfusions enormously and, in particular, have a dramatic consequence on the recipients' health.
PABD-related serious adverse events did not occur in our study. This 1-year cohort is too small to permit a quantitative risk assessment. Considering the 20 years of experience at our institution in PABD, we strongly believe that even patients scheduled for cardiac surgery can be accepted for PABD if they are carefully selected and treated by a team experienced with this special patient population.
In our analysis the wastage rate was approximately 20% for all components. The similar Hb levels in the postoperative course indicated that there was an identical trigger for transfusion of PRC products in both groups and not a more liberal transfusion practice in PABD patients. Such a low wastage rate in the setting of donation and transfusion being performed in the same clinic was the basis of an analysis in our clinic that could demonstrate the cost-effectiveness of PABD [19] .
This matched-pair analysis is not a prospective randomised trial. However, the chosen numerous strict matching criteria led to a cohort with the most reasonable comparability between donors and non-donors with regard to predicting factors of perioperative allogeneic blood transfusion [7] . Therefore, the risk of unrecognised differences in practice should be reduced to a minimum, but it cannot be excluded completely.
In conclusion, PABD is a safe and efficient alternative to allogeneic blood products when the PABD programme is carefully planned and conducted by a team experienced with cardiac surgical patients. Especially the shortage of blood products within the near future should emphasise PABD as an alternative source for blood products for elective surgery.
And second question, do you additionally give erythropoietin in these patients?
Dr Martin: We try to have at least 2 weeks between the last donation and surgery. In some patients it's not possible, so we go down to 7 days before surgery. This is the one point.
Erythropoietin, we never do it. It's too expensive. Dr K. Athanassiadi (Athens, Greece): If the patient has a history of malignancy, would you still on go on with autologous blood transfusion?
Dr Martin: Only if the patient is under full recovery. And this has to be documented.
Dr Grabenwoger: This is from the practical standpoint an important paper. At my unit, for example, we also discuss this with anaesthesiologists to do more autologous blood donation with the patients, but you have the problem that there should be, I've heard, 2-3 weeks in between the last donation and the operation. Then even if there are some problems with the patient, how long can you store the blood? Because maybe then he gets sick or a cold and then you want to operate on him in 2 months and then I think you can use his blood again?
Dr Martin: The maximum storage time is 49 days. This is limited by the banks. And we start maximum 5 weeks before surgery. The date of surgery has to be fixed with our surgeons. So you have 35 days. And there is a time of 12 days, 14 days, you have to recover from a cold, for example.
Dr Grabenwoger: But we always failed with the organisational details of this method. And then most of the patients nowadays have a lot of comorbidities. They are very old, they have high-grade aortic stenosis, they have severe 3-vessel disease or main stem stenosis. And so from the clinical standpoint, I've heard of some troubles to draw a lot of blood from these sick patients in front of the operation.
But of course, there are some advantages, but these advantages are again decreased by the fact that in a high percentage you have to give additional allogeneic blood or blood concentrates. And so I'm personally not really convinced that this is for our patients, the way to go, to make this preoperative autologous blood donation.
Dr R. De Simone (Heidelberg, Germany): What do you think about the practice of taking autologous blood just prior to the operation? It's sometimes a procedure that our anaesthesiologists say can also save some blood. Do you have some experience? Do your anaesthesiologists do the same? Just prior to the operation, prior to going on the machine, if you can save blood in this way.
Dr Martin: You mean the acute normovolaemic haemodilution. We've done this a few years ago, but when we reviewed our data we could not see any effect on the allogeneic transfusion rates, and therefore we no longer do this for the last years.
